The Cooper Companies, Inc. (NASDAQ:COO) Shares Bought by Barclays PLC

Barclays PLC lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 462,947 shares of the medical device company’s stock after buying an additional 3,070 shares during the period. Barclays PLC’s holdings in Cooper Companies were worth $51,082,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. State Street Corp boosted its stake in Cooper Companies by 1.2% during the third quarter. State Street Corp now owns 8,590,689 shares of the medical device company’s stock valued at $947,897,000 after buying an additional 104,521 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its position in shares of Cooper Companies by 3.0% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock valued at $682,738,000 after purchasing an additional 231,155 shares during the period. Victory Capital Management Inc. raised its holdings in Cooper Companies by 23.0% during the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock worth $435,856,000 after buying an additional 737,726 shares during the period. Impax Asset Management Group plc lifted its stake in Cooper Companies by 31.0% during the second quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock valued at $205,511,000 after buying an additional 558,886 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Cooper Companies by 11.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company’s stock worth $200,665,000 after buying an additional 194,118 shares during the period. 24.39% of the stock is owned by institutional investors.

Cooper Companies Trading Down 2.6 %

Shares of NASDAQ:COO opened at $96.72 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $19.26 billion, a PE ratio of 49.60, a P/E/G ratio of 2.17 and a beta of 0.97. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38. The firm has a fifty day moving average price of $103.71 and a 200 day moving average price of $98.87.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm posted $0.87 EPS. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. Analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on COO. Wells Fargo & Company lifted their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Morgan Stanley reduced their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Finally, Citigroup cut their target price on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the transaction, the chief executive officer now owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. The trade was a 41.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.00% of the stock is owned by corporate insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.